CPVL Protein, Human (HEK293, His)

CPVL protein, a serine carboxypeptidase, may be involved in the digestion of phagocytic granules in lysosomes and in the inflammatory protease cascade. CPVL protein, a potential biomarker, may promote glioma progression by inhibiting STAT1 phosphorylation. CPVL Protein, Human (HEK293, His) is the recombinant human-derived CPVL protein, expressed by HEK293 , with C-6*His labeled tag. The total length of CPVL Protein, Human (HEK293, His) is 454 a.a., with molecular weight of 54-65 kDa.

The CPVL protein, a serine carboxypeptidase, may be involved in the digestion of phagocytic granules in lysosomes, in the inflammatory protease cascade, and in the pruning of peptides for antigen presentation. Carboxypeptidases are a large family of proteases that cleave individual amino acids from the carboxyl terminus of proteins or peptides. The functions of these enzymes include the degradation of phagocytic and/or endocytosed proteins in lysosomes and the digestive breakdown of proteins in the intestine. In addition to their degradative functions in the intestine, carboxypeptidases can activate or inactivate bioactive peptides such as angiotensin, bradykinin, and endothelin I. CPVL protein expression is induced during the maturation of monocytes into macrophages. In macrophages, possible functions of CPVL include digestion of phagocytic granules in lysosomes, participation in inflammatory protease cascades, and pruning of peptides for antigen presentation. Studies have found that the expression of CPVL protein is significantly up-regulated in both neovascular AMD (nAMD) and dry AMD, making it a potential biomarker for identification of AMD. Furthermore, high CPVL expression was associated with advanced clinical grade and poor prognosis. CPVL silencing activates the IFN-γ/STAT1 signaling pathway, thereby promoting glioma cell apoptosis and inhibiting cell proliferation and tumorigenicity in vitro and in vivo.

Human

HEK293

C-6*His

AAH16838.1 (L23-G476)

54504  [NCBI]

LFRSLYRSVSMPPKGDSGQPLFLTPYIEAGKIQKGRELSLVGPFPGLNMKSYAGFLTVNKTYNSNLFFWFFPAQIQPEDAPVVLWLQGGPGGSSMFGLFVEHGPYVVTSNMTLRDRDFPWTTTLSMLYIDNPVGTGFSFTDDTHGYAVNEDDVARDLYSALIQFFQIFPEYKNNDFYVTGESYAGKYVPAIAHLIHSLNPVREVKINLNGIAIGDGYSDPESIIGGYAEFLYQIGLLDEKQKKYFQKQCHECIEHIRKQNWFEAFEILDKLLDGDLTSDPSYFQNVTGCSNYYNFLRCTEPEDQLYYVKFLSLPEVRQAIHVGNQTFNDGTIVEKYLREDTVQSVKPWLTEIMNNYKVLIYNGQLDIIVAAALTERSLMGMDWKGSQEYKKAEKKVWKIFKSDSEVAGYIRQAGDFHQVIIRGGGHILPYDQPLRAFDMINRFIYGKGWDPYVG

54-65 kDa

Greater than 95% as determined by reducing SDS-PAGE

<1 EU/μg, determined by LAL method.